Evidence map›Paper›PMID 33552071›Full record

ArticleFrontiers in immunology2020

SIRPα Suppresses Response to Therapeutic Antibodies by Nurse Like Cells From Chronic Lymphocytic Leukemia Patients.

Yu-Chen Enya Chen, Melinda Burgess, Sally Mapp, Peter Mollee, Devinder Gill, Antje Blumenthal, Nicholas A Saunders

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 56% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Yu-Chen Enya ChenDiamantina Institute, University of Queensland, Woolloongabba, QLD, Australia.
Melinda BurgessDiamantina Institute, University of Queensland, Woolloongabba, QLD, Australia.
Sally MappCancer Services Unit, Department of Haematology, Princess Alexandra Hospital, Woolloongabba, QLD, Australia.
Peter MolleeCancer Services Unit, Department of Haematology, Princess Alexandra Hospital, Woolloongabba, QLD, Australia.
Devinder GillCancer Services Unit, Department of Haematology, Princess Alexandra Hospital, Woolloongabba, QLD, Australia.
Antje BlumenthalDiamantina Institute, University of Queensland, Woolloongabba, QLD, Australia.
Nicholas A SaundersDiamantina Institute, University of Queensland, Woolloongabba, QLD, Australia.
Princess Alexandra Hospital · AUThe University of Queensland · AUTranslational Research Institute · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Targeted antibody therapies improve outcomes for chronic lymphocytic leukemia (CLL) patients. However, resistance often develops. We have previously shown that resistance to therapeutic antibodies, by monocyte derived macrophages (referred to as nurse like cells, NLCs), from CLL patients is characterized by suppression of antibody dependent phagocytosis (ADP). The mechanism(s) contributing to the muted ADP responses remain unresolved. In this regard, an innate immune checkpoint was recently described that uses the CD47:SIRPα axis to suppress phagocytic responses by macrophages. In this study we examine whether the SIRPα axis regulates ADP responses to the anti-CD20 antibody, obinutuzumab, by NLCs. Using siRNA depletion strategies we show that SIRPα is a suppressor of ADP responses. Moreover, we show that this innate immune checkpoint contributes to the resistance phenotype in NLCs derived from CLL patients. Finally, we show that SIRPα suppression is mediated

Indexed as

Antibodies, Monoclonal, HumanizedAntigens, DifferentiationAntineoplastic Agents, ImmunologicalLeukemia, Lymphocytic, Chronic, B-CellMacrophagesPhagocytosisReceptors, ImmunologicAntigens, CD20CD47 AntigenCells, CulturedHumansImmunity, InnateProtein Tyrosine Phosphatase, Non-Receptor Type 6Signal TransductionSyk KinaseAntibodies, Monoclonal, HumanizedAntigens, CD20Antigens, DifferentiationAntineoplastic Agents, ImmunologicalCD47 AntigenCD47 protein, humanobinutuzumabProtein Tyrosine Phosphatase, Non-Receptor Type 6Receptors, ImmunologicSIRPA protein, humanSyk KinaseSYK protein, humanantibody dependent phagocytosisantibody resistance 2chronic lymphocytic leukemiamacrophagemacrophagesnurse-like-cells

Identifiers

PMID33552071
PMCPMC7859087
OpenAlexW3125287508

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.